NASDAQ:CELZ Creative Medical Technology Q2 2025 Earnings Results & Report $0.53 -0.09 (-14.35%) Closing price 11/13/2026 03:56 PM EasternExtended Trading$0.54 +0.01 (+1.31%) As of 11/13/2026 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Creative Medical Technology beat analyst earnings expectations in its Q2 2025 results, released August 8, 2025. The company reported EPS of -$0.48 versus the -$0.63 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 8, 2025TimeBefore Market Opens Creative Medical Technology EPS ResultsActual EPS-$0.48Consensus EPS -$0.63Beat/MissBeat by +$0.15One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCreative Medical Technology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Creative Medical Technology Q2 2025 Earnings FAQ Did Creative Medical Technology beat earnings estimates for Q2 2025? Creative Medical Technology (NASDAQ:CELZ) reported earnings of -$0.48 per share for Q2 2025, beating the consensus estimate of -$0.63. The report was announced on Friday, August 8, 2025. Creative Medical Technology Earnings HeadlinesCreative Medical Technology Receives Nasdaq Bid Price Compliance NoticeNovember 13 at 4:51 PM | tipranks.comCreative Medical Technology Holdings, Inc. Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome Knee Osteoarthritis StudyOctober 22, 2026 | marketscreener.comMI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 15 at 1:00 AM | Behind the Markets (Ad)Creative Medical Reports 93% Response Rate In Ultrasome Knee Osteoarthritis Pilot StudyOctober 20, 2026 | rttnews.comCreative Medical Technology Holdings Highlights Positive Ultrasome™ Pilot Data in Knee Osteoarthritis StudyOctober 20, 2026 | quiverquant.comQCreative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis StudyOctober 20, 2026 | globenewswire.comSee More Creative Medical Technology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Creative Medical Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Creative Medical Technology and other key companies, straight to your email. Email Address About Creative Medical TechnologyCreative Medical Technology (NASDAQ:CELZ) is a biotechnology company focused on developing regenerative medicine and cellular therapies. Its research programs are designed to use stem cells and other biological approaches to address conditions for which existing treatment options may be limited. The company has developed and investigated therapies based on autologous stem cells, meaning cells collected from and administered back to the same patient. Its programs have included CaverStem, a regenerative treatment candidate for erectile dysfunction, as well as investigational platforms such as FemCelz for female sexual dysfunction and ImmCelz, an immune-modulating cellular therapy platform. These programs remain subject to clinical development and regulatory requirements. Creative Medical Technology Holdings has historically operated from the United States and has focused primarily on research, development and potential commercialization of regenerative medicine products rather than a broad portfolio of marketed pharmaceuticals. The company’s programs and corporate activities have evolved over time, and the availability or development status of individual candidates may change as clinical and regulatory work progresses.View Creative Medical Technology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/13Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCerebras Q3 Results: How Much More Proof Does Wall Street Need?YETI Beat on Earnings, But Its Sales Tell a Different StoryCostco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsLightPath Technologies' Record Backlog Highlights a Bigger Defense Opportunity Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
